#AS­CO22: En­her­tu blows chemother­a­py out of the wa­ter, re­defin­ing breast can­cer sub­groups along the way

CHICA­GO — When Camille Hertz­ka found out the re­sults of a study show­ing breast can­cer drug En­her­tu cut dis­ease pro­gres­sion or death by about half, the As­traZeneca VP im­me­di­ate­ly thought of the po­ten­tial for pa­tients, some of whom are friends.

Giv­en her po­si­tion lead­ing US med­ical af­fairs for AZ’s on­col­o­gy unit, Hertz­ka of course couldn’t tell her friend with HER2-low breast can­cer the re­sults of the study, but that friend was still top of mind as the Big Phar­ma geared up to present the land­mark re­sults at the an­nu­al AS­CO meet­ing on Sun­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER